SNP number and the average proper_info score.
Statistical analyses
In stage 1, in each study we performed logistic regression association analysis of T2D with genotype dosage using an additive genetic model including as covariates age, sex and principal components derived from the genetic data to account for population stratification. We further applied genomic control (GC) correction to study-level association summary statistics to correct for residual population structure not accounted for by principal components adjustment. We combined the association results using inverse variance-weighted fixed effect metaanalysis using both GWAMA (8) and METAL (9) , and observed identical results. The stage 1 meta-analysis had 11.7M autosomal and 260k chromosome X SNVs that 1) had a total minor allele count >5 and 2) were present in ≥3 studies. The lambda (GC) value was 1.08, while inflation estimates from LDscore regression (10) showed no evidence of population stratification suggesting lambda (GC)=1. We performed inverse variance weighted fixedeffects meta-analysis of the 16 stage 2 Metabochip studies (lambda GC correction applied based on QT-interval variant set (1) ) and the 18 stage 1 studies using GWAMA (8) and METAL (9) software. Heterogeneity was assessed using the I 2 index from the complete study-level meta-analysis. We combined stage 1 and stage 2 results by inverse variance-weighted fixed-effect meta-analysis. We performed a secondary T2D association analysis by modelling body mass index (BMI) as covariate in 15 studies (not including DGDG, GoDARTS and WTCCC). The total sample size for this analysis was 21,440 T2D cases and 97,052 controls, (N eff =70,242). The lambda (GC) was 1.05. Genetic effect sizes (beta coefficients) estimated from models with and without BMI adjustments were compared using a matched analysis within the same subset of 15 studies:
, where and are the estimated genetic effect from models with and without BMI adjustment, is the estimated standard error of the estimates, and ρ is the estimated correlation between and obtained from all genetic variants (ρ =0.90).
Comparison between HapMap and 1000G reference variant sets
We made LocusZoom(11) regional plots of the Stage 1 meta-analysis results indexed by lead SNV for the 13 novel loci, and estimated LD using the EUR 1000G March 2012 variant set (Supplementary Figure 2) . We also made regional plots indexed by the lead 1000G SNV, but otherwise only including SNVs present in the previous HapMap2-imputed analyses (1, 12) .
Power calculations
We performed power calculations 10 over a range of odds ratios (ORs), using the corresponding genotype relative risk (GRR) in the power calculation, to (i) determine the effect size that would yield 80% power based on a grid search and (ii) to provide power estimates for pre-specified ORs, for specified risk allele frequency (RAF). The RAF is defined as the frequency of the allele that increases T2D risk in the stage 1 meta-analysis. We determined power as a function of the GRR, RAF, alpha=5×10 -8 , and the average weighted effective case sample size, assuming a 1:1 ratio of cases and controls. For each variant, we defined weighted effective case sample size as the product of the variant-specific effective case sample size and the average variant-specific imputation quality (based on r 2 hat or info measures available from each included study). To calculate the average weighted effective case sample size, for each RAF we selected the 10,000 stage 1 meta-analysis variants with RAF closest to the target RAF (taking equal proportions of variants above and below the RAF), and took the average of the 10,000 weighted effective case sample sizes. Approximate conditional analysis with GCTA To identify if multiple statistically independent signals were present in known and novel T2D associated regions, we performed approximate conditional analysis in the stage 1 sample using GCTA (v1.24) (13) . Among 70 established T2D-associated and 13 novel loci (p<5×10 -4 ), we analysed SNVs in the 1Mb-window around each lead variant, conditioning on the lead SNV at each locus. We ran the GCTA analysis using three separate genotype reference panels for estimation of LD between variants (14): UK10K project (N=3,621), Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS (15)) study (3,298 T2D cases and 3,708 controls) and Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS (16)) study (n=949). We considered loci as containing distinct signals (in the initial and further rounds of analysis) if a SNV reached locus-wide significance after accounting for region-specific multiple testing (p<10 -5 ) in all three reference panels. Where we observed distinct signals, we then conditioned on the original lead SNV, and the newly observed distinct SNV(s) to detect further signals, until no additional signal was identified at p<10 -5 . We identified six regions with more than one independent signal (18 distinct signals). In each region with multiple signals, for each independent variant we conditioned on all other independent variants in the region and used these results were used for finemapping (below). At KCNQ1, we performed conditioning using GCTA model selection which better handles the large number of independent signals (using the UK10K reference panel).
Finemapping analyses using credible set mapping
The goal of finemapping was to identify sets of 99% credible causal variants for the lead independent variants at known and novel loci. We used credible set fine-mapping (17) within 95 distinct signals (at 82 loci) with T2D-association signals p<5x10 -4 in the present stage 1 to investigate whether 1000G-imputation allowed us to better resolve the specific variants driving these associations (Supplementary Tables 3 and 9 ). We included in the credible set analysis all signals where the lead independent SNV reached p<5x10 -4 in the stage 1 meta-analysis, as SNVs with weak association, mostly those identified in non-European GWASs, generally yield very large credible SNP sets. In regions with multiple independent variants, we used the signal remaining following approximate conditional analysis on all other independent variants in the region (see above). To define the locus boundaries, for each lead SNV we identified the outermost variants from the set of variants in r 2 ≥ .2 with the lead SNV and added an additional flanking region of .02 cM to each side. To perform credible set mapping, the T2D stage 1 meta-analysis results were converted to Bayes' factors (BF) for each variant within the variant/locus boundary (17) . The posterior probability that SNV j was causal was defined by:
where, BF j denotes the BF for the jth SNV, and the denominator is the sum of all included BFs. A 99% credible set of variants was created by ranking the posterior probabilities from highest to lowest and summing them until the cumulative posterior probability exceeded 0.99. To estimate the credible set sizes we would have observed with HapMap imputation-based meta-analysis results, we recomputed the posterior probabilities after first restricting to variants observed in previous HapMap-imputed analyses. T1D/T2D discrimination analysis Given the overlap between loci previously associated with T1D and the newly associated T2D loci, we used an inverse variance weighted Mendelian randomisation approach (18) to test whether this was likely to reflect misclassification of T1D cases as individuals with T2D in the current study. Briefly, using 50 SNVs associated with T1D at genome-wide significance (19) , we tested the association of genetic predisposition to T1D with T2D in the present analysis. If some proportion of T2D cases in the current study actually are T1D, we would expect that the T1D risk variants to consistently predict T2D risk. We performed analysis with and without the lead SNVs showing associations with both T1D and T2D (p<0.05 for T2D).
Expression quantitative trait loci (eQTL) analysis
Lead SNVs at all 13 novel loci mapped to non-coding sequence, leaving uncertain the identities of the effector transcripts through which the T2D-risk effects are mediated. To highlight potential effectors, we first considered RNA expression data, focusing on data from pancreatic islets, adipose, muscle, liver, and whole blood, and seeking coincidence (r 2 >0.8) between the lead T2D-associated SNVs and drivers of regional cis-eQTLs (p<5x10 -6 ) (Supplementary Table 10 ). To look for potential biological overlap of T2D lead variants and eQTL variants, we extracted the lead (most significantly associated) eQTL for each tested gene from existing datasets for pancreatic islets (20) , skeletal muscle (21, 22) , adipose tissue(22-26), liver (22, 24, (27) (28) (29) (30) and whole blood (which has the largest sample size of available eQTL studies) (22, 23, 26, (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . Additional eQTL data was integrated from online sources including ScanDB (http://www.scandb.org/newinterface/about.html), the Broad Institute GTEx Portal (http://www.gtexportal.org/home/), and the Pritchard Lab (eqtl.uchicago.edu). Additional liver eQTL data was downloaded from ScanDB and cis-eQTLs were limited to those with p<10 -6 .We considered that a lead T2D SNV showed potential evidence of influencing gene expression if it was in high LD (r 2 >0.8) with the lead eQTL SNP, and if the lead eQTL SNP had p< 5 x 10 -6
Hierarchical clustering of T2D-related metabolic phenotypes Starting with the T2D associated SNV variants in the finemapping set, we identified sets of variants with similar patterns of T2D related quantitative trait association. For the T2D associated SNVs, we obtained T2D-related quantitative trait z scores from published HapMap-based GWAS meta-analysis for: fasting glucose (FG (48)), fasting insulin adjusted for BMI (FIadjBMI (48)), homeostasis model assessment for beta-cell function (HOMA-B (48)), homeostasis model assessment for insulin resistance (HOMA-IR (48)), 2-h glucose adjusted for BMI (2hGluadjBMI (49)), proinsulin (PR (50)), corrected insulin response (CIR (51)), body mass index (52), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), total cholesterol (TC), triglycerides (TG), all from the Global Lipids Genetics Consortium (53). When the result for a SNV was not available, we used the results from the variant in highest r 2 (r 2 >0.6). We coded the z-scores such that a positive sign indicated that the trait value was higher for the T2D risk allele, a negative sign that the trait value was lower for the T2D risk allele. We performed complete linkage hierarchical clustering and used the Euclidian distance dissimilarity measure L 2 =15% as a threshold to define the loci clusters. We tested the validity of groups through multi-scale bootstrap resampling with 50,000 bootstrap replicates, as described previously(54). All distances, clustering analyses and statistical calculations were done using stats, gplots, pvclust, fpc and vegan packages in the R programming language (R Core Team (2013) Tables 3 and 9) , we used a fractional logistic regression model to compare a binary indicator of variants overlapping a total of 261 functional annotations to the posterior probabilities for association derived from the fine-mapping analysis (π c ) (Supplementary Table 12 ). For each TF, we collapsed all binding sites into one annotation. We then tested for the effect of variants with each cell type and TF annotation on the variant posterior probabilities (π c ) using all variants in the 95 credible regions (ie 100% credible sets). We used a generalized linear model where the dependent variable is π c value for each variant and the predictor variable is a binary indicator of overlap of the variant and the annotation, a (1 if yes, 0 if no). We included several additional binary indicators for generic genebased annotations in the model for each annotation -3UTR (u), 5UTR (v), coding exon (c), and within 1kb upstream of GENCODE Tss (t) -as well as a categorical variable for locus membership (l).
For each annotation, we obtained the estimated effect size and standard error from this model. We then recalculated the standard error using the sandwich variance estimator (R package sandwich). We calculated a zscore by dividing the effect size by the re-estimated standard error, and calculated a two-sided p-value from the zscore. We also applied this model to the three subsets of loci visually identified from the hierarchical clustering as having similar T2D-related trait association patterns. In each analysis, we considered an annotation significant if it reached a Bonferroni-corrected p-value threshold of 2x10 -4 (.05/256 annotations).
Pathway analyses with DEPICT
We used the Data-driven Expression Prioritized Integration for Complex Traits (DEPICT) tool (57) to i) prioritize genes that may represent promising candidates for T2D pathophysiology, and (ii) identify reconstituted gene sets that are enriched in genes from associated regions and might be related to T2D biological pathways. As input we used independent SNVs (LD-pruning parameters: r 2 <0.05 in the 1000 Genomes project phase 1 reference panel including 268 unrelated individuals from CEU, GBR and TSI populations; release date 2011-05-21; physical distance threshold=500kb) selected from the set including stage1 meta-analysis SNVs with p<10 -5 and lead variants at established loci. We then used the DEPICT method (57) to construct associated regions by mapping genes to independently associated SNVs, if they overlapped or resided within LD window (r 2 >.0.5) with the independently associated SNV. Variants within the major histocompatibility complex region (chromosome 6, base pairs 25,000,000 through 35,000,000) were excluded. This gave 206 independent regions covering 328 genes for the analysis with DEPICT. For the calculation of empirical enrichment p values, we used 200 sets of SNVs randomly drawn from entire genome within regions matching by gene density; we performed 20 replications for FDR estimation. For each significantly enriched reconstituted gene set, we plotted the five genes that most strongly mapped to the given gene sets and resided within an associated T2D locus. The mapping strength between a gene and a reconstituted gene set was denoted by a Z-score shown in parenthesis after the gene identifier in Supplementary Table 10 . After the gene set enrichment analysis, we omitted reconstituted gene sets for which genes in the original gene set were not nominally enriched (Wilcoxon rank-sum test). By design, genes in the original gene set are expected to be enriched in the reconstituted gene set; lack of enrichment complicates interpretation of the reconstituted gene set because the label of the reconstituted gene set will be inaccurate. Using this procedure the "Megacephaly" reconstituted gene set was removed from the results. To visualize the 20 reconstituted gene sets with p<10 -5 in Cytoscape (58) (Supplementary Figure 10) , we estimated their overlap by computing the pairwise Pearson correlation coefficient r between each pair of gene sets followed by discretization into one of three bins; 0.3≤ρ<0.5 as low overlap, 0.5≤ρ<0.7 as medium overlap, and ρ≥0.7 as high overlap. Table 3 ). The Yaxis was trimmed at -log 10 (p-value)=40 for easier visualisation; the TCF7L2 association signal (p=1.35×10 -81 ) falls far beyond this range (Supplementary Table 3 ). Supplementary Figure 2. Regional plots for the thirteen novel T2D loci. In the left panel, the plot is based using all 1000 Genomes March 2012 multi-ethnic SNV set, whereas in the right panel the plot is restricted to SNVs present in HapMap CEU reference set. Supplementary Figure 3 . QQ-plot of the expected vs. observed P-values for heterogeneity between BMIadjusted and unadjusted association analysis models for established and novel T2D loci. The FTO, TCF7L2, MC4R and SLC30A8 loci show large differences between models (p heterogeneity =5.70x10 -29 3.51x10 -13 , 5.54x10 -6 and 6.94x10 -5 , respectively). Table 11) . Reconstituted gene sets are represented by nodes and their overlap by edges. Reconstituted gene sets are colour-coded based on their degree of enrichment in genes at the associated T2D loci (darker means more significant). DEPICT identified 21 significantly enriched reconstituted gene sets; one gene set was omitted due to a potential mismatch between the reconstituted gene set identifier and the reconstituted gene set (see Methods). For each gene set, the three genes exhibiting the highest likelihood within the given gene set and being within associated T2D loci are shown. Pairwise overlap between reconstituted gene sets were estimated by computing the Pearson correlation coefficient r between two reconstituted gene sets followed by discretization into one of three bins; 0.3≤ r <0.5 denotes low overlap, 0.5≤ r <0.7 denotes medium overlap, and r≥0.7 denotes high overlap. Edges representing overlap corresponding to r <0.3 are not shown. Supplementary Figure 10 . Type 2 diabetes credible sets are enriched for genomic annotations. We calculated the posterior probability of causality for all variants at 95 established T2D loci. We then tested the effect of variants annotated with protein-coding genes, cell type chromatin state, and transcription factor binding on the posterior probabilities across all loci. We identified significant effects among coding exons and pancreatic islet chromatin, and for binding sites of the FOXA2, NKX2.2, PDX1, and EZH2 transcription factors. Supplementary Figure 11 . Genomic annotation at credible sets of novel loci. A) The T2D signal at the BCAR1 locus contains a variant rs8056814 with a 57% probability of being causal for the signal. This variant overlaps an enhancer active in pancreatic islets proximal to the CTRB1 gene. B) The novel T2D signal at the CMIP locus is also associated with BMI and lipid phenotypes. The variant rs2925979 has a 91% probability of being causal for the CMIP signal and overlaps an enhancer active in liver, which is the most enriched cell type in the BMI/lipid physiology group. of a family of central nervous adhesion molecules It is expressed in the same sub-cortical regions where reward training neuronal pathways are expressed. CMIP: chr16:81534790 (rs2925979). This gene encodes a c-Maf inducing protein that plays a role in the T-cell signalling pathway. C-mip down-regulates NF-κB activity and promotes apoptosis in podocytes (25) in cases of idiopathic nephrotic syndrome (INS). Associations with WHR(26), adiponectin (27) and HDL cholesterol(7) levels have been reported for this same variant. ZZEF1: chr17:4014384 (rs7224685) is an intronic variant in the ZZEF1 (zinc finger, ZZ-type with EF-hand domain 1) gene related to calcium ion binding. This locus was previously implicated in functional impairment in major depressive disorder, bipolar disorder and schizophrenia (28) . GLP2R: chr17:9780387 (rs78761021) is an intronic variant in the glucagon-like peptide 2 receptor (GLP2R) gene belonging to a G protein-coupled receptor superfamily. It is closely related to the glucagon receptor (GCGR) and GLP1R. Glucagon-like peptide-2 (GLP2) is a 33-amino acid proglucagon-derived peptide produced by intestinal enteroendocrine cells. GIP: the nearest gene to the detected signal (chr17:46967038, rs12941263) in this region is ATP5G1, coding for a subunit of mitochondrial ATP synthase and involved in "energy production", in lipid transports and in cellular metabolism. Another gene within locus, GIP encodes an incretin hormone that belongs to the glucagon superfamily and is gastric inhibitory polypeptide. GIP is a potent stimulator of insulin secretion from pancreatic beta-cells following food ingestion and nutrient absorption via its G protein-coupled receptor activation of adenylyl cyclase and other signal transduction pathways (29) . Variants (rs46522, rs318095) in high LD (r 2 =0.97) with our identified SNV at GIP have been associated with susceptibility to coronary heart disease(11) and height (30) . Variation in the receptor for GIP (GIPR) have previously been associated with glycemic traits and T2D (31, 32) .
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